Cardoz: Anti-inflammatory synergy

Over the past decade, it's become clear that atherosclerosis is a chronic inflammatory disease to which inflammatory cells, in particular mast cells, are major contributors. Based on this shift in the understanding of disease pathology, Cardoz AB believes its combination products targeting the inflammatory components of atherosclerosis and lipoproteins may provide benefit over current treatments.

Cardoz's

Read the full 550 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE